TP53 and neoplasm: While treatment-specific, posttranslational modifications, such as acetylation at lysine 317, phosphorylation at serine 33 or cofactor interactions, have been hypothesized to mediate p53-mediated gene expression and/or binding [1],[2],[32],[33], this may not be the case for some established tumor cell lines [34].